All I can do is a range which states while exact figures, rather...

All I can do is a range which states while exact figures, rather indicative. If the company is sold < $20 / share very disappointed, $21 to $40 / share disappointed. $41 to around $70 / share kind of OK can't complain, $71 to $100 / share happy, > $100 / share over the moon. I personally believe based on Bisantrene's history, recent data and potentials based on information from public sources, no of shares, company's management with DT at the helm if the clinical trials are at Stage 2 and all current assumptions (and hopes) validated, these prices could be real. Some of you may think I am irrealistic and delusional, I don't care just state what I think, whether it is right or wrong.